Skip to main content
SpringerLink
Log in

Harnblasenkarzinom

  • Chapter
Therapiekonzepte Onkologie

  • 66 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bloom HJG, Hendry WFWallace DM, (1982) Treatment of T3 bladder cancer: controlled trial of preoperative radiotherapy and radical cystectomy versus radical radiotherapy. Second report and review. Brit J Urol 54:136

    Article  CAS  Google Scholar 

  2. Boccardo FGiuliani L , et al. (1992) Prophylaxis of superficial bladder carcinoma with MMC or rh-Interferon alpha 2b. Preliminary results of a multicentric Italian study. European Urology (Abstract) 282:162

    Google Scholar 

  3. Bredael JJ, Croker BP, Glenn DF (1980) The curability of invasive bladder cancer treated by radical cystectomy. Eur Urol 6:206

    PubMed  CAS  Google Scholar 

  4. Brendler CB, Schlegel PN, Walsh PC (1987) Urethrectomy with preservation of potency. J Urol 144:270

    Google Scholar 

  5. Burch PA, Richardson RL, Cha SS, Camoriano JK (1997) Combination paclitaxel and cisplatin is active in advanced urothelial carcinoma (UC). Proc Am Soc Clin Oncol Vol 16, A 329:1175

    Google Scholar 

  6. Coppin CML, Gospodarowicz MK, James K, Tannock IFZee B, Carson J, Pater J, Sullivan LD, for the National Cancer Institute of Canada Clinical Trials Group (1996) Improved Local Control of Invasive Bladder Cancer by Concurrent Cisplatin and Preoperative or Definitive Radiation. J Clin Oncol 14 (11): 2901–2907

    PubMed  CAS  Google Scholar 

  7. Debruyne FJG, van der Meijden PM (1987) BCG versus mitomycin C intravesical therapy in patients with superficial bladder cancer: First results of a randomized prospective trial. J Urol 137:179 A

    Google Scholar 

  8. Eberle J, Wohlgemut M, Bartsch G (1993) Results of combined radio- and chemotherapy for invasive bladder cancer, (in press)

    Google Scholar 

  9. Huland E, Huland H (1989) Local continuous hig dose interleukin 2: A new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 49:5469

    PubMed  CAS  Google Scholar 

  10. Igawa M (1994) Limitations of M-VAC chemotherapy for the treatment of advanced bladder carcinoma. J Urol 144:662

    Google Scholar 

  11. Khandekar JD, Elson PJ, de Wys WD, Slayton REHarris DT, (1985) Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated cell carcinoma of the urinary tract. J Clin Oncol 3:539

    PubMed  CAS  Google Scholar 

  12. Krege S, Giani G, Meyer R, Otto T, Rübben H (1996) A randomized multi-center trial of adjuvant therapy in superficial bladder cancer. J Urol 156:962–966

    Article  PubMed  CAS  Google Scholar 

  13. Lamm DL (1993) Vitamins in superficial bladder cancer. J Urol 149:279

    Google Scholar 

  14. Lamm DL, Blumenstein B, Sarosdy M, Grossman B (1997) Significant long term patient benefit with BCG maintenance therapy. J Urol 157:213

    Article  Google Scholar 

  15. Loehrer PJ, Elson P, Kuebler JP, Crawford ED, Tannock I, Raghavan D, Stuart-Harris R, Trump DEinhorn LH, (1990) Advanced bladder cancer. A prospec-tiv intergroup trial comparing single agent cisplatin (CDDP) vs M-VAC combination therapy (INT 0078) (Meeting abstract). Proc Am Soc Clin Oncol 9: A511

    Google Scholar 

  16. Logothetis CJ, Dexeus FH, Fin L, Sella A, Amato RJ, Ayala AG, Kilboum RG (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050

    PubMed  CAS  Google Scholar 

  17. Logothetis CJ, Hossan B, Sella A, Dexeus FH, Amato RJ (1991) Fluorouracil and recombinant human interferon alpha-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors. J Natl Cancer Inst 33:285

    Article  Google Scholar 

  18. Lundholm C, Norlen BS, Ekman P, Sahnson S, Lagerkuist M, Lindeborg F, Olsson SL, Tueter K, Wiskstrom H, Westberg R, Malström PU (1996) A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus cal-mette-guerin in patients with superficial bladder carcinoma. J Urol 156 (1): 372–376

    Article  PubMed  CAS  Google Scholar 

  19. van der Maase H, Andersen L, Crino L, Weißbach L, Dogliotti L (1997) A phase II study of gemcitabine and cisplatin in patients with transitional cell carcinoma (TCC) of the urothelium. Proc Asco Vol 16, A 324:1155

    Google Scholar 

  20. Malkowicz SB, Nichols P, Lieskovsky G, Boyd STD, Huffmann J, Skinner DG (1990) The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, PI, PIS and P2). J Urol 144:641

    PubMed  CAS  Google Scholar 

  21. McCaffrey JA, Hilton S, Mazumdar M, Spicer J, Meegan G, Kelly WK, Herr H, Sheinfeld J, Scher HI, Bajorin DF (1997) A phase II trial of ifosfamide, paclitaxel and cisplatin (ITP) in patients (pts) with transitional cell carcinoma (TCC). Proc Asco Vol 16, A324:1154

    Google Scholar 

  22. McLaren B, Callagher CJ, Maseon M, Melesi G, Oliver RTD (1997) Paclitaxel, vinblastine, cisplatin (PCV) in patients with advanced transitional cell cancer (TCC). Proc Asco Vol. 16, A337:1205

    Google Scholar 

  23. van der Meijden APM, Kurth K-H, Oosterlinck W, Debruyne FMJ, and Members of the EORTC Genito-Urinary Group (1992) Intravesical therapy with Adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group. Cancer Chemother Pharmacol 30 (Suppl) :95–98

    Article  Google Scholar 

  24. Miller LS (1977) Bladder cancer: superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer 39:973

    Article  PubMed  CAS  Google Scholar 

  25. Niijima T, Koiso K, Akaqza H (1983) Randomized clinical trial on chemopro-phylaxis of recurrences in cases of superficial bladder cancer. Cancer Chemother Pharmacol 11:79

    Article  Google Scholar 

  26. Otto T, Bex A, Krege S, Walz P, Rübben H (1994) Paclitaxel-based second line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1): A clinical phase II study Cancer, (in press)

    Google Scholar 

  27. Redman B, Hussain M, Smith D, Mertens W, Flaherty L (1997) Phase II evaluation of paclitaxel and carboplatin in advanced urothelial cancer. Proc Asco Vol 16, A 325:1157

    Google Scholar 

  28. Roehrborn CG, Sagalowsky AJ, Peters PC (1991) Long-term patient survival after cystectomy for regional metastatic transitional cell carcinoma of the bladder. J Urol 146:36

    PubMed  CAS  Google Scholar 

  29. Roth BJ, Finch DE, Birhle R, Rowland RG, Foster RF, Collins M, Fox SWilliams SD, (1997) Proc Asco Vol 16, A324:1156

    Google Scholar 

  30. Rübben H, Lutzeyer W, Fischer N, Deutz F-J, Giani G (1988) Natural history and treatment of low and high risk superficial bladder tumors. J Urol 139:283

    PubMed  Google Scholar 

  31. RUTT (Registry for Urinary Tract Tumors: Harnwegstumorregister) (1985) Jahresbericht. Verh Dtsch Ges Urol 37:665

    Google Scholar 

  32. Schnack B, Grbovic M, Brodowicz T, Wittschke C, Marberger M, Zielinski CC (1997) High effectivity of a combination of Taxol® with Carboplatin in the treatment of metastatic urothelial cancer. Proc Asco Vol 16, A325:1159

    Google Scholar 

  33. Stadler WM, Murphy B, Kaufman D, Raghavan D, Voi M (1997) Phase II trial of gemcitabine (GEM) plus cisplatin (CDDP) in metastatic urothelial cancer (UC). Proc Asco Vol 16, A 324:1152

    Google Scholar 

  34. Sternberg CN, Yagoda A, Scher HJ, Whitmore WF Jr, Watson RC, Hollander PS, Morse MJ, Herr HW, Sogant PCFair WR, (1986) Surgical staging and long term survival in patients with advanced transitional cell carcinoma (TCC) of the uro-thelium treated with M-VAC. Proc Am Soc Clin Oncol 5:390

    Google Scholar 

  35. Stoter G (1985) Chemotherapy of metastatic bladder carcinoma. J Urol 3:110

    Google Scholar 

  36. Vieweg J, Gschwend J, Fair WR (1997) Recurrent bladder cancer following radical cystectomy — patterns of failure, prognosis and implications for treatment. J Urol 157(4)(Suppl):384

    Google Scholar 

Download references

Authors
  1. T. Otto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Bex
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Rübben
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Otto, T., Bex, A., Rübben, H. (1998). Harnblasenkarzinom. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10493-4_47

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10493-4_47

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-63821-6

  • Online ISBN: 978-3-662-10493-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation